HC Wainwright initiated coverage on Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA), a commercial-stage biopharmaceutical firm ...

H.C. Wainwright initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a buy rating, citing its negative enterprise ...

英为财情Investing.com - Vanda Pharmaceuticals (NASDAQ: VNDA )星期三发布了第三季度的财报，数据显示，公司营收逊于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.09，总营收为$47.7M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$50.75M，每股收益为$-0 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vanda (VNDA – Research Report) and Vigil ...

Vanda Pharmaceuticals ( (VNDA) ) has released its Q3 earnings. Here is a breakdown of the information Vanda Pharmaceuticals presented to its ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript November 6, 2024 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.

Vanda Pharmaceuticals Inc. VNDA) on Wednesday reported a loss of $5.3 million in its third quarter. The Washington-based company said it had a loss of 9 cents per share.

Hello, and thank you for standing by. At this time, I would like to welcome you to the Q3 2024 Vanda Pharmaceuticals Inc. Earnings Conference Call. All lines has been placed on mute to prevent any ...

H.C. Wainwright initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a buy rating, citing its negative enterprise value. The investment bank said its rating was based on Vanda’s well ...